TNFAIP2 and prostate adenocarcinoma: Although TNFAIP2 expression was reported upregulated in several types of cancers, including breast cancers, glioma, and nasopharyngeal carcinoma [16, 22, 23, 43], the current study demonstrated that TNFAIP2 was also found to be downregulated in different types of tumors including adrenocortical carcinoma, kidney renal clear cell carcinoma, prostate adenocarcinoma, etc., indicating that TNFAIP2 was expressed in a tissue-specific manner.